Comparative Pharmacology
Head-to-head clinical analysis: COLYTE FLAVORED versus PORTALAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLYTE FLAVORED versus PORTALAC.
COLYTE-FLAVORED vs PORTALAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colyte is an osmotic laxative that induces diarrhea by retaining water in the colon through non-absorbable polyethylene glycol (PEG) and electrolytes, resulting in bowel cleansing.
Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to short-chain fatty acids (e.g., acetic, lactic, and formic acid), resulting in acidification of colonic contents and an increase in osmotic pressure, which stimulates bowel evacuation. In hepatic encephalopathy, acidification reduces blood ammonia levels by converting NH3 to NH4+ in the colon, inhibiting ammonia absorption.
4 liters orally as a single dose or in divided doses for colonoscopy preparation, or 1 liter orally every 10-15 minutes until 4 liters are consumed.
Initial: 15-30 mL (10-20 g lactulose) orally, 2-3 times daily; titrate to 2-3 soft stools daily. For acute hepatic encephalopathy: 30-45 mL (20-30 g) orally every hour until evacuation, then 3-4 times daily.
None Documented
None Documented
Not applicable; the drug acts locally in the gastrointestinal tract without significant systemic absorption. For the small fraction absorbed, a terminal elimination half-life of approximately 0.5-1 hour is estimated, but clinical relevance is negligible.
1.7-2.0 hours (terminal); clinical context: short t1/2 allows rapid dose adjustment in hepatic encephalopathy.
Primarily eliminated in feces (≥95%) as intact drug via the gastrointestinal tract. Minimal systemic absorption; renal excretion accounts for <1% of the administered dose.
Renal: ~40% as unchanged drug; fecal: ~60% as metabolites (biliary excretion of conjugates and lactulose).
Category C
Category C
Osmotic Laxative
Osmotic Laxative